四環醫藥(00460.HK):抗癲癇藥獲內地上市許可
四環醫藥(00460.HK)公布,全資附屬北京四環開發的拉考沙胺片(50mg及100mg)已於2021年9月1日獲得國家藥監局頒發的《藥品註冊批件》,批准該藥品生產,視同通過質量和療效一致性評價。
拉考沙胺片適用於16歲及以上癲癇患者部分性發作的聯合治療,副作用小,不經過肝臟代謝,與其他抗癲癇藥物不會產生有臨床意義的重大藥物相互作用,並且由於其獨特的作用機制,可作為部分癲癇發作患者新的治療選擇。
四環醫藥預計集團開發的拉考沙胺片將很快上市銷售。同時,憑藉自有原料藥等優勢,有望在未來生產過程中降低成本,預期對經營業績產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.